Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Melanie M. Frigault"'
Autor:
Hideo Saka, Dana Ghiorghiu, Yuichiro Ohe, Helena A. Yu, Leora Horn, Suresh S. Ramalingam, Geoffrey R. Oxnard, J.C.-H. Yang, Helen Mann, Kenneth S. Thress, Karthick Vishwanathan, Melanie M. Frigault, Myung-Ju Ahn, Sang We Kim, Koichi Goto
Publikováno v:
Annals of Oncology. 31:507-516
Background Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was designed to assess the safety and tolerability of osimertinib in combi
Autor:
Benedetta Lombardi, J. Carl Barrett, Veerendra Munugalavadla, Paola Marco-Casanova, Andrew J. Pierce, Melanie M. Frigault, Elizabeth A. Harrington, Natalia Lukashchuk
Publikováno v:
Journal of visualized experiments : JoVE. (169)
Analysis of biomarkers in peripheral blood is becoming increasingly important in clinical trials to establish proof of mechanism to evaluate effects of treatment, and help guide dose and schedule setting of therapeutics. From a single blood draw, per
Autor:
Michael Millward, Chuan Qi, Jian Wang, Jason D. Lickliter, Weiguo Su, Ye Hua, Lilin Zhang, Liu Yang, Yang Sai, Hui K Gan, Shethah Morgan, Melanie M. Frigault
Publikováno v:
Clinical Cancer Research. 25:4924-4932
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human cancers. This phase I study assessed the safety, tolerability, and MTD of the potent and selective MET inhibitor, savolitini
Autor:
Priti Patel, Raquel Izumi, Cheng Quah, Bruce D. Cheson, John N. Allan, Morton Coleman, Thomas J. Kipps, Dan Jones, Min Hui Wang, Philip A. Thompson, Melanie M. Frigault, Rakesh K. Raman, Jeff P. Sharman, Kerry A. Rogers
Publikováno v:
Haematologica
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Autor:
Remy B. Verheijen, Yongqian Shu, Wei Li, Nong Yang, Caicun Zhou, Anders Mellemgaard, Coumaran Egile, Jian Fang, Ryan J. Hartmaier, Yi-Long Wu, Xiao-Qing Liu, Jianxing He, Liu Yang, Melanie M. Frigault, Jian-An Huang, Jianhua Chang, Shethah Morgan, Jin-Ji Yang, Gongyan Chen, Ghada F. Ahmed
Publikováno v:
Investigational new drugs. 39(2)
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended first-line treatments in EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC). However, acquired resistance (e.g. MET amplification) is frequently observed. Sa
Autor:
Mathilde Cancel, Toni K. Choueiri, Zsolt Szijgyarto, Sabina Signoretti, Jae-Lyun Lee, Remy B. Verheijen, Laurence Albiges, Anders Mellemgaard, Anne L’Hernault, Melanie M. Frigault, Daniel Y.C. Heng, Lone Ottesen
Publikováno v:
JAMA oncology. 6(8)
Importance Papillary renal cell carcinoma (PRCC) is the most common type of non-clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, vol
Autor:
Priti Patel, Dih-Yih Chen, Olivier Tournilhac, Thérèse Aurran-Schleinitz, Raquel Izumi, Efstathios Kastritis, Sheeba K. Thomas, Ahmed Hamdy, Monique C. Minnema, Francesco Forconi, Helen McCarthy, Richard R. Furman, Pier Luigi Zinzani, Diana Mittag, Shirley D'Sa, Daniel Reif Greenwald, Marie José Kersten, Simon Rule, Sunil Iyengar, Harriet S. Walter, Jaimal Kothari, Roger G. Owen, Sun Ku Lee, Melanie M. Frigault, Helen Wei, Bruce D. Cheson
Publikováno v:
The Lancet Haematology
The Lancet Haematology, Elsevier, 2020, 7 (2), pp.e112-e121. ⟨10.1016/S2352-3026(19)30210-8⟩
The Lancet Haematology, 2020, 7 (2), pp.e112-e121. ⟨10.1016/S2352-3026(19)30210-8⟩
Lancet haematology, 7(2), e112. Lancet Publishing Group
Lancet. Haematology, 7(2), e112-e121. Lancet Publishing Group
The Lancet Haematology, Elsevier, 2020, 7 (2), pp.e112-e121. ⟨10.1016/S2352-3026(19)30210-8⟩
The Lancet Haematology, 2020, 7 (2), pp.e112-e121. ⟨10.1016/S2352-3026(19)30210-8⟩
Lancet haematology, 7(2), e112. Lancet Publishing Group
Lancet. Haematology, 7(2), e112-e121. Lancet Publishing Group
Summary Background Chemoimmunotherapy is typically the standard of care for patients with Waldenstrom macroglobulinemia; however, infectious and hematologic toxic effects are problematic. Acalabrutinib is a selective, potent Bruton tyrosine-kinase in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b08811b4c09666e7e36fe58d1ae7b6a
https://hal.uca.fr/hal-02885323
https://hal.uca.fr/hal-02885323
Autor:
John C. Byrd, Raquel Izumi, Min Hui Wang, David M. Weiss, Cheng Quah, Veerendra Munugalavadla, Seema A. Bhat, Michael Gulrajani, Melanie M. Frigault, James S. Blachly, Gerard Lozanski, Mojgan Jianfar, Kerry A. Rogers, Barbara L. Andersen, Jennifer A. Woyach, Ahmed Hamdy
Publikováno v:
Cancer Discov
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23162eb0f19e1b3d22d3d6fb6fa3ae62
https://europepmc.org/articles/PMC8176161/
https://europepmc.org/articles/PMC8176161/
Autor:
Xiaoqing Liu, Ryan J. Hartmaier, Caicun Zhou, Anders Mellemgaard, Jianhua Chang, Jian-An Huang, Remy B. Verheijen, Yongqian Shu, Jian Fang, Melanie M. Frigault, Jianxing He, Shethah Morgan, Yi-Long Wu, Gongyan Chen, Liu Yang, Jin-Ji Yang, Nong Yang, Coumaran Egile, Ghada F. Ahmed, Wei Li
Publikováno v:
SSRN Electronic Journal.
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended first-line treatments in EGFR- mutated non-small-cell lung cancer (NSCLC). However, acquired resistance (e.g. MET amplification) is common. Savolitini
Autor:
Farrukh T. Awan, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kathleen A. Burke, Todd Covey, Priti Patel, Paolo Ghia, Min Hui Wang, Susan O'Brien, Jennifer R. Brown, John M. Pagel, Richard R. Furman, Deborah M. Stephens, Stephen Devereux, William G. Wierda, Jennifer A. Woyach, Anna Schuh, Jorge M. Chaves, Peter Martin, John C. Byrd, Michael Gulrajani, Jacqueline C. Barrientos, Peter Hillmen
Publikováno v:
Blood
Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is an oral, highly selective BTK inhibitor that all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28fefc85a53d96e7a80d33105bccd073